Investigational drug · Phase 2
EN001 Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells
Also called: WJ-MSCs, EN001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Sarcopenia, Charcot-Marie-Tooth Disease Type 1A.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "EN001 Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells"
First trial start
2024
May 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EN001 Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sarcopenia
- Charcot-Marie-Tooth Disease Type 1A
Largest trials
Live from ClinicalTrials.gov: studies naming "EN001 Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells" as an intervention, largest first.
- Evaluate the Efficacy and Safety of EN001 in Patients With SarcopeniaPivotal-lookingNot yet recruiting
ENCellIndustry
NCT07808905 · 132 participants (planned) · Start Mar 1, 2027 · Primary completion Oct 31, 2029
Drug: EN001; EN001 and 4 more · For: Sarcopenia
Sites: Seoul, South Korea
- Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular DystrophyStatus unknown
ENCellIndustry
NCT06328725 · 88 participants (planned) · Start Mar 2024 · Primary completion Nov 2025
Drug: EN001 · For: Duchenne Muscular Dystrophy
Sites: Seoul, South Korea · 2 sites in all
ENCellIndustry
NCT06328712 · 27 participants (planned) · Start May 30, 2024 · Primary completion Dec 31, 2026
Drug: EN001; EN001 Placebo · For: Charcot-Marie-Tooth Disease Type 1A
Sites: Gyeongju, South Korea; Seoul, South Korea · 3 sites in all
ENCellIndustry
NCT05338099 · 7 participants · Start Jan 18, 2022 · Primary completion Dec 28, 2022
Drug: EN001; EN001 · For: Duchenne Muscular Dystrophy
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Mesenchymal Stem Cells From a Klinefelter Syndrome Patient: Functional Characterization and Therapeutic Implications.
Zychowicz M, Lech W, Figiel-Dabrowska A, et al. · Andrology 2027
- Hybrid spheroids of urine-derived renal epithelial cells: Structural and functional characterization.
Pizzuti V, Balducelli E, Bin S, et al. · Biochem Biophys Rep 2026
- Wharton's jelly insufficiency and its implications for perinatal outcomes and regenerative medicine: A review.
Habiba UE, Shamim S, Sarwar I, et al. · Biomol Biomed 2026
- Wharton's jelly-derived mesenchymal stem cells improve the in vitro culture of fresh and cryopreserved prepubertal ovine (Ovis aries) testicular tissue.
Té S, Llacho CPH, Ñaupas LVS, et al. · Theriogenology 2026
- WJ-MSCs modulate Treg phenotypic and transcriptional profiles in T1DM: comparative insights into direct and indirect mechanisms.
Ursavaş S, Canbaz HT, Ay EN, et al. · Cytotherapy 2026
- Feeder-free expansion and early cardiomyogenic commitment of a human umbilical cord blood-derived cell population with very small embryonic-like stem cell (VSEL)-Like features.
Iliadou A, Gounari E, Papameletiou E, et al. · Differentiation 2026
Also in development for Sarcopenia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.